Your participant did not wake up this morning and just decide to withdraw. This has been a long time coming.
People in clinical trials rarely decide to withdraw on a single day. There are almost no single events that will cause someone to withdraw without prior warning. A massive adverse reaction, an argument with a staff member, or something traumatic might lead to an immediate withdrawal, but these are rare.
Very often, however, patients withdraw because of a thousand tiny cuts.
These can include having to drive too far, dealing with excessive paperwork, adhering to complex rules, or not fully understanding the implications of the clinical trial.
People may withdraw from your trials, and for a proportion of them it is inevitable. It is important to follow up to understand why they withdrew, not just for the trial at hand but also to inform future trials and keep iterating to drive down withdrawal rates.
You’ll be able to see the trend lines. Some of the reasons I’ve noticed recently include:
- “There’s a lot of time you’re not paying me for.”
- “I feel better already, so why should I keep going?” (the antibiotic conundrum).
- “The trial is just a pain to be part of.”
- “The drug doesn’t seem to be having any effect.”
- “I must be on the placebo.”
All these are reasons people drop out of clinical trials. It’s crucial to know what those reasons are and address them well in advance to avoid losing participants.
We all know that every time you start losing patients in your clinical trial, you’re essentially starting over again.
What are you doing to make sure your participants stay in your clinical trials and to address their pain points before they reach the point of wanting to quit? Much of the answer sits before day one. Eligibility is not readiness. A person who understood what the study would ask of their life before they joined has fewer cuts to accumulate.
Making Patients Heard Throughout the Research Journey
Clinical research works best when people are involved at every stage. Too often, their perspectives are a last-minute idea or ignored altogether. This limits study relevance, enrollment success, and real-world impact. Early and continued patient input makes research more ethical, efficient, and effective.
A lack of direct patient involvement results in trial designs that fail to meet participant needs and leads to burdensome protocols, recruitment challenges, and retention issues. Involving people from the start creates studies designed with patients from concept to completion.
Patient input strengthens clinical research by identifying barriers, improving accessibility, and shaping trial endpoints that matter to patients. Researchers who actively listen gain insights that drive practical improvements in trial conduct and data quality.
Embedding Patient Voices Early
Patient involvement should begin before study protocols are finalized. Asking people how they experience their condition, what matters most in their treatment, and what barriers they face to participation informs better trial design. Understanding their needs means designing studies that align with daily life, rather than expecting participants to accommodate complex, impractical trial protocols. Instead of assuming what is feasible, researchers should invite patients into the discussion and treat them as essential contributors. When people share their experiences, they highlight logistical and emotional challenges that might otherwise go unnoticed.
Many research protocols are structured around clinical convenience rather than participant practicality. By involving patients before study initiation, investigators gain valuable insight into what might deter or encourage participation. Long visit schedules, excessive travel, and overly complex procedures are often cited as key barriers. Addressing these factors early helps in structuring trials that people can realistically commit to. Researchers must ask themselves: how easy is it for a person to take part in this study? If the process feels cumbersome or disruptive, participation rates will suffer.
Involving patient advocates and advisory groups can significantly improve study design. Their input helps ensure that endpoints align with real patient concerns and that recruitment materials are understandable and transparent. This collaborative approach results in stronger enrollment, greater study compliance, and improved data quality. People who feel their voices matter are more likely to stay involved throughout the research process, contributing to more robust and meaningful findings.
Sustaining Engagement Throughout Research Collaboration
It’s not enough to seek patient input at the outset and move on. Ongoing collaboration ensures studies remain patient-friendly. Patients should have channels to share their experiences as the trial progresses. Engagement should not be a one-time consultation but a continuous effort to ensure that research remains aligned with real-world patient experiences. Regular check-ins, patient surveys, and advisory boards can help trial teams stay connected to participant concerns.
Research collaboration benefits from patient advisory groups that review study updates, participant materials, and evolving challenges. Researchers should actively seek feedback on participant experience throughout the study lifecycle. When people feel heard, they are more likely to stay in the study and offer useful suggestions on ways to improve the trial process.
Effective communication is crucial. Many trials use complex language that alienates people, making it difficult to understand procedures, risks, and expectations. Study materials should be jargon-free, clear, and adapted to different levels of health literacy. Too often, participants report feeling confused or overwhelmed by research documents. If information is not accessible, retention declines. Researchers should focus on clarity, transparency, and responsiveness to questions, ensuring that participants always feel informed and valued.
Improving Accessibility and Reducing Burdens
One of the biggest reasons for patient dropout is difficulty. Studies designed without patient input impose impractical travel, time, or procedural burdens. Patients are already dealing with the complexities of managing their condition; they shouldn’t have to navigate a demanding research process. Easier participation improves both recruitment and retention.
Researchers need to explore flexible participation models. Home-based and virtual visits can reduce unnecessary travel and make trials more accessible to a wider demographic. Remote monitoring technologies allow real-time data collection without frequent site visits. Reimbursements and logistical support remove barriers for those who do have to travel.
Underrepresentation remains a significant issue. Many marginalized populations face additional obstacles due to financial constraints, language barriers, or mistrust. Inclusive recruitment strategies must be implemented for research to benefit everyone, not just those with the means to participate. Accessibility creates more representative and equitable trials.
Another key factor in accessibility is the burden of study procedures. Long hospital stays, excessive testing, and cumbersome data collection methods discourage participation. Where possible, trial teams should streamline procedures, focusing on what is essential for scientific validity while minimizing unnecessary effort for participants. A study designed with patients considers both the scientific goals and the human experience of taking part in research.
Recognizing Patients as Partners
Patients contribute valuable expertise about their condition. They are not just participants but partners in research. Researchers must keep them updated on study outcomes and the impact of their contributions. Far too often, people feel like passive subjects rather than active collaborators. Research teams must recognize them as equal stakeholders to strengthen trust with the patient community.
Patients deserve to know how their participation has contributed to research. Researchers should provide summaries of study results to demonstrate transparency and make sure participants are not left wondering about their involvement. A lack of feedback discourages future participation and undermines the credibility of clinical research.
Research collaboration should not end with the study. Continued dialogue with patient advocacy groups improves future research initiatives. Participants can become powerful advocates for clinical research, helping to spread awareness and encourage others to take part. Their experiences provide insight that researchers may not otherwise consider, keeping trials relevant and practical.
An approach built around people improves both study results and the wider clinical trial landscape. When patient voices are heard from the earliest planning stages to post-study communication, researchers build more effective and ethical trials. See what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, so that understanding a study comes before anyone is asked to join one. Understanding comes first. Decisions follow.